Pawel Leznicki’s Post

I'm glad to share our latest review article, written in collaboration with Frédéric Perros, titled "Novel Insights into the GCN2 Pathway and Its Targeting: Therapeutic Value in Cancer and Lessons from Lung Fibrosis Development," published in The FEBS Journal https://lnkd.in/d9hskDPi This review highlights recent findings on the role of GCN2 in both stressed and non-stressed cells. We also discuss its involvement in the development of cancer and lung diseases, questioning the potential of targeting GCN2 for human health benefits. We hope you find this review insightful.

I'm thrilled to share that our latest paper, titled "Novel insights into the GCN2 pathway and its targeting: Therapeutic value in cancer and lessons from lung fibrosis development," has been published in The FEBS Journal. 🎉 Co-authored with the brilliant Cédric Chaveroux and team, this review delves into the intricate mechanisms of the GCN2 pathway, highlighting its crucial role in cell adaptation to environmental stress and its therapeutic potential in cancer treatment. We also explore the complex interplay of GCN2 in lung diseases, including its roles in cancer progression, pulmonary fibrosis, and pulmonary hypertension. https://lnkd.in/dAAZvUTc

New research explores the structural basis for the activation and filamentation of glutaminase, a key enzyme in cancer cell metabolism. The study uncovers the impact of phosphate and inhibitors on glutaminase activity and filament formation, shedding light on potential therapeutic targets for cancer treatment. Read more 👉 https://lnkd.in/eCinP8Wr #MolecularBiology #CancerResearch #Glutaminase #NewResearch

🔬 Miao et al.'s research reveals how SMYD5-mediated RPL40 methylation plays a crucial role in ribosome elongation, connecting translation output with hepatocarcinoma development. This discovery positions SMYD5 as a potential target for cancer therapy, highlighting the broader significance of lysine methylation. Dive into the details: https://lnkd.in/e2xEbk4d #CancerResearch #TranslationRegulation #SMYD5 #MedicalResearch #CancerTreatment

#MEK inhibitors target mitogen-activated protein kinase (MAPK) signaling pathways, which regulate cell growth and proliferation. They offer targeted therapy for cancer by inhibiting aberrant MAPK signaling in tumor cells, leading to growth arrest and apoptosis. MEK inhibitors have shown efficacy in various cancers, including melanoma, non-small cell lung cancer, and pancreatic cancer, offering promising treatment options for patients with advanced or metastatic disease. https://lnkd.in/gtmwvpzt

𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗮𝗻𝗱 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗼𝗳 𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗺𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘀𝗺 𝗳𝗼𝗿 𝗮𝗻𝘁𝗶𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 As an Austrian, I'm especially happy to share a publication from a research group at Medical University of Vienna today - especially as it's in a topic that I keep coming back to: immunometabolism. https://lnkd.in/dNc_49UE This review provides a balanced discussion about both the opportunities and challenges in targeting macrophage metabolism in cancer therapy. As you'd expect, energy metabolism (glycolysis, TCA metabolism) - but it definitely goes far beyond that. For tryptophan metabolism, it discusses approaches beyond IDO. It discusses the role of arginine and nitric oxide as well as lipid and fatty acid metabolism. Finally, the need for biomarkers is discussed as one of the open questions in targeting TAM metabolism. Full publciation: Piyal Saha, Paul Ettel, Thomas Weichhart (2024). Leveraging macrophage metabolism for anticancer therapy: opportunities and pitfalls. Trends in pharmacological sciences, S0165-6147(24)00045-2. Advance online publication. https://lnkd.in/d87gm2zb. Freely avialable under a Creative Commons license: https://lnkd.in/d72Y4gs6 If you're interested in the topic, here's another recent review on the role of macrophage metabolism in the context of anticancer therapy. https://lnkd.in/dNR4vkis #science #metabolism #pharmacology #oncology #immunometabolism

🚀 LenioBio supports breakthrough in protein expression! Congratulations to the authors (Alex Snow et. al.) of a groundbreaking study that achieved a milestone in cancer research by synthesizing the oncogenic fusion protein, FGFR3-TACC3, using the ALiCE cell-free protein expression system. Overcoming the challenges of producing receptor tyrosine kinases, this method enabled the generation of fully functional proteins in just 48 hours. This advancement accelerates research into oncogenic RTKs and promises to expedite the development of targeted cancer treatments. 🔬 Key Findings: 💫 Successful Protein Production: The study demonstrated the capability of ALiCE microsomes to synthesize functional FGFR3-TACC3, a significant leap forward in protein expression. 💡 Innovative Solubilization: The researchers utilized SMA lipid particles for efficient extraction of membrane protein complexes, preserving their structural integrity and activity. 🎖 Exceptional Protein Quality: Functional assays show high-quality protein output, eliminating the need for extensive optimization. The study highlights the enabling and revolutionary potential of cell-free systems in advancing cancer research and treatment development. Check out the full study 👉 https://lnkd.in/epavJUzY

Excited to share this research! This work discusses the influence of hyaluronic acid (HA) on U87-MG, a popular glioblastoma (GBM) cell line, from a metabolic standpoint. While HA is popularly know to alter GBM prognosis, very little is known about its influence on the fundamental functioning of a cancer cell. This research aims to bridge this gap! https://lnkd.in/gSJ2N562 

Natural way of #P13Kinhibitor drugs in advanced #cancer. Dysregulation of PI3K/Akt/mTOR pathway generates a favorable oncogenic environment and has been seen in a variety of transformed cells and human tumors. High frequency of #mutations of the components (such as PTEN, TSC, and PI3K) in this pathway is correlated to human malignant progression and poor prognosis. A mutation of #mTOR (L2431P) within an autoinhibitory domain of mTOR, resulting in constitutively activation of mTOR, has also recently been documented]. Of interest, the tumor cells that are addictive to PI3K/Akt/mTOR signaling are more sensitive to their inhibitors than normal cells. Therefore, targeting PI3K/Akt/mTOR pathway has become a new and promising strategy to combat cancer. #resveratrol #turmeric #fasting #greentea #broccoli #sulphorafene #soybean #vitaminE #tocotrienols #fightobesity #fightinsulinresistance #berberine https://lnkd.in/dAPJQXj4

I'm thrilled to announce the publication of my first review paper. Here, Carsten Uhd Nielsen and I explore the intricate world of amino acid transporters, shedding light on their inhibitors and their potential use in cancer treatment. What particularly intrigued me was the prevalence of inhibitors based on amino acid scaffolds. However, despite the advancements in uncovering new inhibitors, many amino acid transporters still lack potent or selective inhibitors, highlighting the vast opportunities for further exploration and discovery in this field. If you're intrigued by the role of amino acid transporters in cancer or fascinated by the discovery of solute carrier inhibitors, I invite you to dive into our publication. Let's uncover the untapped potential of amino acid transporter inhibitors! 🌟